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The poor solubility of a large number of active pharmaceutical ingredients (API) is a major challenge in pharmaceutical 
research. Therefore, the extrusion of amorphous solid dispersions (ASDs) is one promising approach to enhance the 
dissolution rate by molecularly dissolve the API in an amorphous carrier polymer. During ASD development, crucial 
parameters as the dissolution and the decomposition need to be monitored. Within this study, a small scale twin screw 
extruder was coupled with special ColVisTec UV-Vis probes that are characterized by their small dimensions. This setup 
enables a systematic formulation development and optimization based on in-line monitoring of crucial parameters using 
small amounts of material. 
 





A large number of the active pharmaceutical ingredients 
(API) that are on the market and the majority of those 
currently under development have a low solubility 
[Rodriguez-Aller, 2015]. However, the dissolution 
process is crucial for the systematic absorption of the 
active ingredient in the human body. A low solubility of 
APIs therefore often leads to a low bioavailability and 
thus an insufficient efficacy.  
A common approach to improving bioavailability is to 
increase the rate of dissolution of the API by 
administering it in the amorphous state in which the 
energy to overcome the crystal lattice has already been 
applied. For the kinetic stabilization of the amorphous 
state, the active ingredient is embedded in an amorphous 
carrier polymer with high viscosity, creating an 
amorphous solid dispersion (ASD) [Vasconcelos, 2007]. 
Hot melt extrusion (HME) enables a solvent-free 
production of ASDs by mixing and dispersing processes 
inside the extruder. In order to process the highly 
viscous polymers, extrusion processes are usually 
carried out at elevated temperatures. Furthermore, the 
solubility temperature has to be reached, which states 
the minimum required temperature for a specific API 
content to be soluble in the carrier polymer. However, 
extrusion at elevated temperatures can cause mechanical 
as well as thermal decomposition, especially if polymer 
or API molecules are thermally unstable [Matić, 2020]. 
In ASD development, this interplay of completely 
dissolve the API and simultaneously avoid 
decomposition is a major challenge. Therefore, 
appropriate process conditions need to be identified 
during early stage process development. Within this 
study, the integration of an in-line UV-Vis 
spectrophotometer during small scale extrusion of ASDs 
is evaluated in order to develop a fast-working method 





Two formulations with different drug loads were 
investigated. Griseofulvin (GRI) (Fagron, Rotterdam, 
Netherlands) and Itraconazole (ITR) (Ria International 




Copovidone (PVPVA) (Plasdone S-630, Ashland Inc., 
Switzerland) was used as carrier polymer.  
Extrusion 
The extrusion was carried out using a DSM xplore micro 
compounder (Xplore Instruments BV, Sittard, 
Netherlands), a laboratory scale extruder with two 
intermeshing conical screws, a capacity of about 5 ml, 
and a die diameter of 3 mm. An air-cooled hopper was 
used in order to prevent the materials from sticking. 3 g 
of formulation were fed into the extruder, respectively. 
The screw speed was set to 50 rpm throughout the whole 
study. The residence time of the material was set by 
operating the extruder in the recirculation mode. 
Therefore, the valve between the screw tips and the die 
was turned to the recirculation channel and opened 
immediately after the desired residence time. The 
material temperature was adjusted by the barrel 
temperature and calibrated beforehand by using a Testo 
875 IR camera (Testo SE & Co. KGaA, Lenzkirch, 
Germany). 
A systematic parameter study was performed for three 
different drug weight fractions w, as listed in Table 1. 
Seven different temperatures in specific distance ΔT to 
the expected solubility temperature Ts were selected 
[Gottschalk, 2021]. For each temperature, the extrusion 
was performed with three different residence times t in 
order to investigate its influence in addition.  
Table 1: Process conditions during the extrusion of 
GRI/PVPVA and ITR/PVPVA. 
Parameter Unit Values 
w (GRI/PVPVA) [-] 0.15, 0.20, 0.25 
w (ITR/PVPVA) [-] 0.25, 0.30, 0.35 
Residence time [min] 1, 3, 10 
ΔT to Ts  [K] -10, -7, -3, 0, 3, 7, 10 
 
Optical analysis 
The presence of remaining drug crystals and coloring 
was investigated by a visual method. Therefore, the 
extrudates were placed on a black background and 
besides a yellowish coloring it was detected, whether 
they are transparent or opaque. Thereby, a transparent 
extrudate was assessed as an amorphous solid dispersion 
whereas an opaque extrudate was considered to contain 
unresolved crystals. 
UV-Vis spectroscopy 
The in-line UV-Vis spectroscopy was performed with an 
Inspectro X spectrophotometer (ColVisTec, Berlin, 
Germany) in the transmission mode. Due to the small 
dimensions of the extruder and the die channel a special 
pair of ColVisTec probes was implemented into the 
experimental setup that differ from the standard TPMP 
probes. A range of 224 to 820 nm and a sampling rate of 
1 Hz was chosen. The obtained spectra were calibrated 
by using spectra of the pure polymer as a blank 
reference.  
 
RESULTS AND DISCUSSION 
In addition to the optical analysis and transmission 
spectra (data not shown), the extrusion of ADSs is 
evaluated based on the L* and b* value of the CIELAB 
color specification system. More specifically, the 
lightness increases with an increasing L* value, 
indicating the API dissolution in the polymer. Color 
changes from blue to yellow are represented by the b* 
value. 
 
Figure 1: L* value of GRI/PVPVA/0.15 as a function 
of temperature and residence time. 
Exemplary results shown for GRI/PVPVA/0.15 in 
figure 1 clearly indicate that the L* value increases with 
increasing temperature. In addition, an increase in the 
L* value with increasing residence time can be seen for 
a certain temperature. In particular at the temperatures 
of 156 °C, 159 °C and 162 °C, the major changes of L* 
values for different residence times can be found in 
comparison to the other temperatures. This shows that 
by reaching the solubility temperature of 159 °C and in 
a small temperature range of 3 °C below and above the 











t =   1 min
t =   3 min




solubility temperature, an increasing lightness occurs. 
Here, the active ingredient is increasingly dissolved in 
the carrier polymer, so that the crystalline components 
decrease and the lightness increases as a result. 
 
Figure 2: b* value of GRI/PVPVA as a function of 
temperature and residence time. 
Figure 2 shows the influence of the residence time and 
the temperature on the b* value for GRI/PVPVA/0.15. 
An increase in the b* value can be seen for both 
increasing temperatures and increasing residence times. 
This is caused by an increasing thermal and mechanical 
stress resulting in material decomposition and thus a 
yellow or brown discoloration of the ASDs. Similar 
trends were also obtained for the other formulation 
ITR/PVPVA as well as for any drug weight fraction 
(data not shown). 
 
CONCLUSIONS 
A special UV-Vis probe, which measures low material 
quantities inside the small scale extruder, was integrated 
into the process. Based on a comparison with an optical 
inspection of the extrudates, the suitability of the in-line 
UV-Vis spectroscopy was confirmed. With the 
transmission spectra and the lightness value L*, 
remaining crystalline components were detected and 
thus the formation of ASDs could be assessed. Since 
color values were also determined, conclusions 
regarding the material decomposition were drawn.  
The influence of temperature and residence time on the 
formation of ASDs was quantified. By comparing the 
temperature required for dissolution with the 
temperature of decomposition for a specific API content 
and residence time, suitable process regimes can be 




The authors thank ColVisTec (Andreas Berghaus) and 




Gottschalk, T.; Grönniger, B.; Ludwig, E.; Wolbert, F.; 
Feuerbach, T.; Winck, J.; Sadowski, G.; Thommes, M. 
(2021): Influence of residence time in manufacturing 
amorphous solid dispersions via hot melt extrusion. In: 
Proceedings of the 12th World Meeting on 
Pharmaceutics, Biopharmaceutics and Pharmaceutical 
Technology 
Matić, J., Alva, C., Witschnigg, A., Eder, S., Reusch, K., 
Paudel, A.; Khinast, J. (2020) Towards predicting the 
product quality in hot-melt extrusion: Small scale 
extrusion. In: International journal of pharmaceutics: X 
2, 100062. DOI: 10.1016/j.ijpx.2020.100062 
Rodriguez-Aller, M.; Guillarme, D.; Veuthey, J.-L.; 
Gurny, R. (2015) Strategies for formulating and 
delivering poorly water-soluble drugs. In: Journal of 
Drug Delivery Science and Technology 30, 342–351. 
DOI: 10.1016/j.jddst.2015.05.009 
Vasconcelos, T.; Sarmento, B.; Costa, P. (2007): Solid 
dispersions as strategy to improve oral bioavailability of 
poor water soluble drugs. In: Drug discovery today 12, 
1068–1075. DOI: 10.1016/j.drudis.2007.09.005 
 











t =   1 min
t =   3 min
t = 10 min
https://doi.org/10.24355/dbbs.084-202110270940-0
